|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: GLB1L3 |
Gene summary for GLB1L3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | GLB1L3 | Gene ID | 112937 |
| Gene name | galactosidase beta 1 like 3 | |
| Gene Alias | GLB1L3 | |
| Cytomap | 11q25 | |
| Gene Type | protein-coding | GO ID | GO:0005975 | UniProtAcc | Q8NCI6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 112937 | GLB1L3 | RNA-P6T2-P6T2-1 | Human | Lung | IAC | 2.31e-18 | 5.45e-01 | -0.0166 |
| 112937 | GLB1L3 | RNA-P6T2-P6T2-2 | Human | Lung | IAC | 2.12e-26 | 6.94e-01 | -0.0132 |
| 112937 | GLB1L3 | RNA-P6T2-P6T2-3 | Human | Lung | IAC | 5.10e-22 | 6.35e-01 | -0.013 |
| 112937 | GLB1L3 | RNA-P6T2-P6T2-4 | Human | Lung | IAC | 8.40e-12 | 4.36e-01 | -0.0121 |
| 112937 | GLB1L3 | RNA-P7T1-P7T1-1 | Human | Lung | AIS | 2.37e-02 | 3.64e-01 | -0.0961 |
| 112937 | GLB1L3 | RNA-P7T1-P7T1-3 | Human | Lung | AIS | 2.91e-02 | 3.23e-01 | -0.0822 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| GLB1L3 | SNV | Missense_Mutation | rs769500802 | c.1004C>T | p.Ser335Phe | p.S335F | Q8NCI6 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A2-A0CU-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
| GLB1L3 | SNV | Missense_Mutation | novel | c.1028G>A | p.Gly343Asp | p.G343D | Q8NCI6 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A7-A26G-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD |
| GLB1L3 | SNV | Missense_Mutation | c.680N>G | p.Glu227Gly | p.E227G | Q8NCI6 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| GLB1L3 | SNV | Missense_Mutation | c.1441G>A | p.Glu481Lys | p.E481K | Q8NCI6 | protein_coding | tolerated(0.49) | benign(0.003) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| GLB1L3 | SNV | Missense_Mutation | c.422N>G | p.Leu141Arg | p.L141R | Q8NCI6 | protein_coding | deleterious(0.01) | possibly_damaging(0.53) | TCGA-AO-A0JB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD | |
| GLB1L3 | SNV | Missense_Mutation | novel | c.1897N>T | p.Val633Phe | p.V633F | Q8NCI6 | protein_coding | deleterious(0) | benign(0.245) | TCGA-LL-A73Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | SD |
| GLB1L3 | insertion | Frame_Shift_Ins | novel | c.1157_1158insGATTTTCCTATCTACTTTCCTTCCTTCTGTATGTTCAT | p.Lys387IlefsTer13 | p.K387Ifs*13 | Q8NCI6 | protein_coding | TCGA-AN-A04A-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | ||
| GLB1L3 | SNV | Missense_Mutation | rs550517910 | c.548N>A | p.Arg183Gln | p.R183Q | Q8NCI6 | protein_coding | tolerated(0.26) | benign(0) | TCGA-EK-A3GM-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
| GLB1L3 | SNV | Missense_Mutation | c.1627N>G | p.Thr543Ala | p.T543A | Q8NCI6 | protein_coding | tolerated(0.21) | benign(0.013) | TCGA-A6-5665-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| GLB1L3 | SNV | Missense_Mutation | c.1350N>T | p.Gln450His | p.Q450H | Q8NCI6 | protein_coding | deleterious(0) | possibly_damaging(0.742) | TCGA-AA-3848-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
| Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |